Evidence map›Paper›PMID 35839759›Full record

ReviewCell2022

Metabolic analysis as a driver for discovery, diagnosis, and therapy.

Ralph J DeBerardinis, Kayvan R Keshari

Open access · hybridAbstract readReview
In one paragraph

Review in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 164 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Metabolic syndrome is associated with accelerated brain aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ralph J DeBerardinisHoward Hughes Medical Institute and Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ralph.deberardinis@utsouthwestern.edu.
Kayvan R KeshariDepartment of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: rahimikk@mskcc.org.
Children's Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7M
Metabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
Leveraging fructose transport to create a privileged substrate to selectively fuel T cellsR01CA248364 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari · 2021 to 2026
$4.3M
Development of large-field-of-view hyperpolarized MRIR01CA237466 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CUNNINGHAM, CHARLES H., HRICAK, HEDVIG · 2020 to 2024
$3.4M
Visualizing oxidative stress using hyperpolarized magnetic resonanceR01CA252037 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2020 to 2024
$3.3M
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyR01CA249294 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KESHARI, KAYVAN R, MERGHOUB, TAHA · 2021 to 2025
$2.6M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA237466NCI NIH HHS R01 CA248364NCI NIH HHS R01 CA249294NCI NIH HHS R01 CA252037NCI NIH HHS R35 CA220449NIDDK NIH HHS P30 DK127984
6 · The paper itself

Abstract

Metabolic anomalies contribute to tissue dysfunction. Current metabolism research spans from organelles to populations, and new technologies can accommodate investigation across these scales. Here, we review recent advancements in metabolic analysis, including small-scale metabolomics techniques amenable to organelles and rare cell types, functional screening to explore how cells respond to metabolic stress, and imaging approaches to non-invasively assess metabolic perturbations in diseases. We discuss how metabolomics provides an informative phenotypic dimension that complements genomic analysis in Mendelian and non-Mendelian disorders. We also outline pressing challenges and how addressing them may further clarify the biochemical basis of human disease.

Indexed as

GenomicsMetabolomicsDiagnostic ImagingHumansgenomicsmagnetic resonancemetabolismmetabolomicsmolecular imagingpositron emission tomographystable isotopes

Identifiers

PMID35839759
PMCPMC9469798
OpenAlexW4285404902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.